Literature DB >> 31149523

Pathologic complete response after gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma.

Takaaki Tatsuguchi1, Kunihito Gotoh1,2, Shogo Kobayashi1,2, Kei Asukai1, Akira Tomokuni1, Hirofumi Akita1, Hiroshi Wada1, Hidenori Takahashi1, Masayuki Ohue1, Masahiko Yano1, Masato Sakon1.   

Abstract

We report the case of a 72-year-old man who was initially diagnosed with far advanced intrahepatic cholangiocarcinoma, associated with bulky lymph node metastasis involving the common hepatic artery and moderate amount of ascites around the liver. After 10 cycles of systemic chemotherapy combining gemcitabine and S-1 with well-tolerated toxicities, a CT scan showed a marked shrinkage of the liver mass and lymph nodes (clinical partial response) with disappearance of ascites, which could permit a radical resection of the tumor. He underwent left lobectomy of the liver with lymph node dissection, and histopathological examination revealed pathologic complete response. Seven years after surgery, he is in a good overall condition.

Entities:  

Keywords:  Gemcitabine (GEM); Intrahepatic cholangiocarcinoma (ICC); Pathologic complete response (pCR); S-1

Year:  2018        PMID: 31149523      PMCID: PMC6498247          DOI: 10.1007/s13691-018-0327-0

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  3 in total

1.  Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and literature review.

Authors:  Surong Hua; Junyi Gao; Qiang Xu; Xiafei Hong; Wenming Wu
Journal:  Gland Surg       Date:  2022-02

Review 2.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

3.  LncRNA TUG1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells by Inhibiting miR-29a.

Authors:  Wei Yuan Hao; Li Wen Guo; Jun Luo; Guo Liang Shao; Jia Ping Zheng
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.